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Abstract
The area of “deprescribing” has rapidly expanded in recent years as a positive intervention to reduce inappropriate
polypharmacy and improve health outcomes for (older) people with multimorbidity. While our understanding of
deprescribing as a process has greatly improved and existing approaches all have patient-centered elements, there
is still limited literature exploring the importance of the individual patient context in deprescribing decision-making.
This is clearly an important consideration to ensure that any deprescribing approach is ethical, respectful, and successful.
To address this gap in the literature, we have developed a conceptual framework in the form of a rainbow – with five
different deprescribing determinants – and place the person at the center of the deprescribing process. This framework
is informed by literature on patient-centered care for older people and people with multimorbidity. We illustrate the
potential application of this framework to a complex patient case to highlight the importance of the different clinical,
psychological, social, financial and physical deprescribing determinants, and how this approach could be adopted by
those working in clinical practice.
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Background
A clear example of “too much medicine” is inappropriate
polypharmacy in older people. Polypharmacy – usually de-
fined as taking 5 or more medications [1] – is very com-
mon: recent estimates suggest that around 25 to 40% of
adults aged over 65 years are prescribed at least 5 medica-
tions [2] – and a significant proportion of such medica-
tions are considered “inappropriate” [3]. While older
people can benefit from taking multiple medications, in-
appropriate polypharmacy – where harms outweigh the
benefits – can be a significant risk and cost to the individ-
ual older patient, as well as society in general. Indeed, in-
appropriate polypharmacy can lead to the development of
adverse drug events, which may cause adverse drug reac-
tions, drug-drug interactions, hospitalization and, in some
cases, death [4]. Taken together, inappropriate polyphar-
macy poses a unique dilemma regarding the balance of
benefit and harm, autonomy and justice [5, 6].
As part of the Choosing Wisely movement and efforts
to reduce low value care, a large body of literature has
emerged focusing on deprescribing [7–9], which has been
described as ‘the process of withdrawal of an inappropriate
medication, supervised by a health care professional with
the goal of managing polypharmacy and improving out-
comes’ [10]. In view of this, a number of protocols have
been developed that help identify inappropriate polyphar-
macy [11, 12] and consider the process of deprescribing
[13, 14]; these protocols seek to support healthcare profes-
sionals when making complex decisions about stopping or
reducing medications. Although most of these protocols
incorporate elements of patient-centered care, a key chal-
lenge that has been somewhat overlooked is that the feasi-
bility and effectiveness of deprescribing greatly depends
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on the individual patient context [15, 16]. For example,
deprescribing medication when a patient is nearing the
end of life may require a completely different approach
when compared to deprescribing medication in an other-
wise healthy older adult [17, 18]. It makes intuitive sense
to take a patient centered approach to deprescribing, after
all the patient is a unique expert on his or her personal
circumstances, goals and preferences. It is also supported
by studies showing that patient centered care and involv-
ing patients in decisions generally has a positive effect on
patient–clinician communication as well as patient in-
volvement and patient outcomes, such as knowledge, sat-
isfaction, confidence in the decision, adherence, quality of
life and health outcomes [19–24]. Reviews in the context
of polypharmacy and deprescribing show positive effects
of patient-centered interventions on knowledge, satisfac-
tion, identification of medication related problems [25]
and suggest that interventions that require active patient
involvement are more effective than interventions that do
not [26].
The aim of this paper is to put the person at the center of
the deprescribing process, with the underlying assumption
that deprescribing will be more successful if it is respectful
of the individual patient context and circumstances.
Similar to current discussions around prescribing guide-
lines [27], deprescribing protocols are important as a sum-
mary of the best available evidence and an outline of the
different deprescribing steps. We argue that additional re-
sources are needed to help clinicians and patients deter-
mine if deprescribing is appropriate given their context,
and determine how medications can be carefully ceased or
doses reduced to achieve the best health goals and out-
comes desired by the patient. To achieve our aim, we have
developed a conceptual framework in the form of a depre-
scribing rainbow (Fig. 1), outlining the clinical, psycho-
logical, social, financial and physical determinants that
should be considered in conjunction with clinical depre-
scribing guidelines and together with the patient when de-
ciding to undertake an episode of deprescribing to ensure
the process has the best chance of success (Table 1). This
framework incorporates principles of patient-centered
communication and decision-making for people with
multimorbidity and the concept of Minimally Disruptive
Medicine [16, 28–32]. The rainbow analogy highlights the
heterogeneity of the older population and how
patient-centered deprescribing needs to acknowledge this
diversity and individuality [16]. A rainbow, which has been
previously used as a model to conceptulise health [33],
also symbolizes that deprescribing should be recognized
as a positive intervention aimed at improving outcomes
important to the patient, and that the relationship be-
tween these factors is fluent and may change over time.
We illustrate the potential application of the deprescribing
rainbow to a hypothetical patient case to highlight the
importance of the five deprescribing determinants, as de-
scribed below. The hypothetical case was initially devel-
oped from the clinical experience of authors AT, JJ, AM; it
was then discussed informally with healthcare profes-
sionals who have responsibility for prescribing medication
to older people to ensure the case was realistic and rele-
vant to clinical practice; finally, and importantly, the case
was discussed and refined with a patient and carer group,
and also with co-author JC, who is a health consumer rep-
resentative for this work, to ensure it was relevant and
meaningful to patients and other healthcare users.
A hypothetical case example showing polypharmacy in
an older adult
Mrs. EF is a 66-year old female who has recently been
diagnosed with stage IV lung cancer, specifically with
squamous cell histology; she is currently undergoing
chemotherapy treatment with carboplatin and gemcita-
bine with palliative intent. Based upon her current dis-
ease status, her life expectancy is estimated to be
approximately 12 months. Her co-morbid health condi-
tions include COPD, hypertension, atrial fibrillation, and
depression for which she is prescribed the following
medications:
 Salbutamol inhaler ‘1 puff when required’
 Tiotropium inhaler ‘1 puff once daily’
 Bendroflumethiazide 2.5 mg ‘one tablet once daily’
 Lisinopril 20 mg ‘one tablet once daily’
 Atenolol 50 mg ‘one tablet once daily’
 Paracetamol 500 mg ‘two tablets four times daily’
 Morphine sulphate MR 10mg ‘one tablet twice daily’
 Senna 7.5 mg ‘two tablets at night’
 Citalopram 20 mg ‘one tablet once daily’
 Aspirin 75 mg ‘one tablet once daily’
 Lansoprazole 15 mg ‘one capsule once daily’
 Warfarin 3 mg adjusted per INR (target INR
range 2–3)
Fig. 1 The deprescribing rainbow highlighting the clinical,
psychological, social, financial and physical determinants that should
be considered when deciding to undertake an episode of deprescribing
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Table 1 Deprescribing context: examples of clinical, psychological, social, financial and physical factors to take into accounta
aThe elements of the deprescribing rainbow are informed by literature on patient-centered care for older people and people with multimorbidity [16, 28–32]
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 Simvastatin 40 mg ‘one tablet at night’
 Calcium 500 mg ‘one tablet twice daily’
EF continues to smoke around 15 cigarettes per day,
and has done for the last thirty years; she does not drink
any alcohol. She is married, and has two children who
are both at University studying Medicine; her husband
recently had an ischemic stroke: as such, EF believes it is
essential to keep her blood pressure under control, as
she, too, is anxious she might have a stroke one day –
especially since her cancer diagnosis. In view of this, she
has recently purchased a blood pressure machine to
monitor her, and her husband’s, blood pressure; she does
this at least three times a week, and yesterday her sitting
blood pressure was 127 / 75mmHg, while her standing
blood pressure was 107 / 63 mmHg. She is pleased with
this result, and believes the medication must be “doing
its job”. She tolerates her antihypertensive medications
reasonably well, but admits the atenolol makes her feel
“tired all the time”.
To keep her cholesterol under control, she previously
only ever ate fresh fruit and vegetables, although since her
cancer diagnosis, this has become less important to her, as
she wants to spend time with her husband when he eats
out at restaurants with friends. She acknowledges her chol-
esterol might increase through this lifestyle change, but is
not too worried, as she is also taking her simvastatin.
EF also buys a calcium supplement from the local
health food shop; she takes this to keep her bones
“strong”. She has used this supplement for a number of
years, and started to take it, because after reading in a
magazine, she learned that the bisphosphonate medica-
tion her doctor previously prescribed for osteoporosis
can cause “esophageal cancer”. EF believes that, as cal-
cium is a “natural mineral”, it is not really a drug in the
true sense of the word, and is 100 % “safe”.
Out of all of her medication, EF ranks taking the war-
farin as the most important: this is because her eldest son,
a fourth-year medical student, who has recently spent
time in an INR clinic on placement, has explained that
warfarin is a “blood thinner” and prevents clots from
forming. Even though she believes the warfarin gives her
terrible constipation, she has promised her son that she
will continue to take it. This is in contrast to the aspirin,
which she also understands is a blood thinner, but it is not
as “strong” as her warfarin; as the aspirin gives her indi-
gestion, she often misses doses, but is comfortable with
this knowing the warfarin will still “do its job”.
She manages her medication quite well, although ac-
knowledges that she does not have the energy to drive
to the doctor’s surgery anymore to order her repeat
medication prescriptions. Nowadays, because of her lung
cancer, she relies on the local pharmacy to deliver her
medications; this can also be challenging, as, in recent
times, she frequently misses the delivery driver, as she is
often at the hospital attending various medical out-
patient appointments.
Even though EF does not really like taking medication,
and has difficultly in swallowing some of her tablets, she
explains that, as she has paid into a medical insurance
plan all of her life, she wants something back from her
policy, and even if her medications only give her the
smallest benefit, she still wants to continue to take them.
Discussion
The hypothetical case of Mrs. EF is clearly complex: her
medication record and medical history highlight complex
multimorbidity and examples of inappropriate polyphar-
macy [34], and Mrs. EF would likely benefit from depre-
scribing some of her medicines. We consider the
hypothetical case of EF in the context of the deprescribing
rainbow, as described below. We describe a process of
identifying which clinical, psychological, social, financial
and physical determinants are a priority for a patient.
The rainbow is intented to be used in conjunction with
clinical deprescribing frameworks (see Additional file 1 in
which the elements of the rainbow are discussed in rela-
tion to the well-cited deprescribing framework by Scott
and colleagues [14]). Example questions that can be used
to support the translation of the deprescribing rainbow
into clinical practice are shown in Additional file 2. These
questions are informed by literature on patient centered
communication and patient centered deprescribing.
Deprescribing is a time consuming (often ongoing)
process, involving many different healthcare professionals.
A comprehensive and interdisciplinary approach is re-
quired to ensure that deprescribing is patient centered
and takes into account the complex patient context. Simi-
lar to, for example, a comprehensive geriatric assessment,
this could take place over multiple consultations and
could involve different types of healthcare professionals,
depending on the context.
Clinical determinants
The patient has stage IV lung cancer with diminished
life expectancy; EF also has a number of comorbid
health conditions, including COPD, hypertension, atrial
fibrillation, and depression. Her last blood pressure read-
ing was 127 / 75mmHg (standing) and 107 / 63 mmHg
(sitting), suggesting that EF has postural hypotension.
This increases the risk of EF having a fall – and the risk
of harm from a fall is further compounded because Mrs.
EF is receiving the anticoagulant warfarin. The patient
has reported a number of adverse effects that are likely
from (or worsened by) her current medications: atenolol
causes fatigue, morphine causes constipation, while the
aspirin causes dyspepsia. Owing to these adverse effects,
EF regularly misses doses of the aspirin, although
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remains compliant with atenolol and morphine. Mrs. EF
has also experienced some prescribing cascades: lanso-
prazole to treat epigastric adverse effects of aspirin,
senna to treat the constipation adverse effects of mor-
phine [35]. Based on even the best evidence, the number
needed to treat and the time to benefit for simvastatin
[36] and calcium [37] suggest there is a level of futility
in their use in Mrs. EF given her life expectancy. Mrs.
EF is also taking a number of medicines that are consid-
ered “high risk” in vulnerable older people, including di-
uretics, opioid analgesics and anticoagulants [38]. From
a clinical standpoint alone, the following preventative
medications have questionable clinical benefit in this pa-
tient given her prognosis, and could be considered for
deprescribing: lisinopril, bendroflumethaizide, atenolol,
aspirin, warfarin, simvastatin, and calcium [34].
Psychological determinants
Due to her anxieties about having a stroke, the patient
believes it is vitally important to have low blood pres-
sure; this is linked to her husband’s previous history of
ischemic stroke. Mrs. EF has a CHA2DS2-VASc Score
for Atrial Fibrillation Stroke Risk of 2 (or higher given
her history of cancer) suggesting she is in the
moderate-high risk range of ischemic stroke. While Mrs.
EF believes it is important to have low blood pressure,
the clinical reality is that it could cause her more harm
than benefit owing to the increased risk of having a fall.
However, it is well known that both clinician and pa-
tients tend to overestimate the benefits of medicines and
underestimate the harms [39, 40]. The literature suggests
that an individualised approach is warrented for EF [41]
– with a consensus guideline suggesting a target systolic
blood pressure of 160–190 mmHg would be adequate
[42]. Before there is any discussion or consideration of
stopping or reducing the antihypertensive medication,
her misguided beliefs about hypertension should be ad-
dressed. The fact that EF measures her blood pressure at
home is also important context to the case, as reducing
or stopping the anti-hypertensive medication may cause
her blood pressure to increase, which may cause her
substantial anxiety. If these issues are not acknowledged
and overcome, it is likely that any attempt to stop or re-
duce the antihypertensive medication would be unsuc-
cessful. It is also possible that, despite having a
discussion about hypertension, EF might not be ready –
from a psychological perspective – to reduce or stop her
medication; it is important in this context that the pre-
scriber is supportive of EF’s decision. Failure to acknow-
ledge this psychological determinant, may have a
negative influence on EF regarding any future depre-
scribing decisions.
The next psychological factor relates to EF’s wish to
spend more time with her husband by eating out with
friends. Her previous anxieties around having a poor diet
have reduced, although taking the simvastatin appears
important to EF in this regard, and may provide some
positive reinforcement to eating out with her husband.
While trial evidence suggests that stopping statins in this
patient group is safe [43, 44], discontinuing this medica-
tion may cause her anxiety to return, which in turn, may
act as a barrier to her eating out, and thus spending time
with her husband. It should be explained to EF that, al-
though the statin will reduce her cholesterol, it is un-
likely that this will give her any survival benefit; she
should be encouraged to eat out with her husband, and
that it is perfectly safe to do so, without the need for the
statin therapy. In contrast to her blood pressure, EF is
unlikely to be in a situation where she can routinely
monitor her cholesterol; this context may help promote
effective deprescribing of the statin.
The final point for the psychological determinants re-
lates to the calcium, which is being used by the patient
to prevent osteoporosis. EF believes that because the cal-
cium is a natural supplement, it is free from harm. This
belief is further strengthened in that she purchases the
calcium from a health food shop, rather than a phar-
macy. Evidence from the literature suggests that the ef-
fectiveness of calcium therapy for osteoporosis is limited
[37]; while the calcium is unlikely to cause significant
harm, EF is also using a thiazide diuretic and has malig-
nant disease, which could increase the possibility of de-
veloping hypercalcemia. Any discussion around stopping
the calcium should address the issue that all medications
– whether purchased over the counter or prescribed by
their physician – can have harmful effects.
Social determinants
An important consideration in relation to the social de-
terminants of deprescribing is associated with the war-
farin and aspirin, and how this relates to EF’s family – in
particular, the eldest son, a fourth-year medical student.
EF has made a promise to her son that she will continue
to take the warfarin which provides important context
to the case. Considerations for stopping warfarin without
involving the son in the decision-making process may
have negative consequences for their relationship. The
fact that EF has recently spent time in an INR clinic
adds further emphasis to this point. Previous literature
has shown that, in the context of life limiting illness,
caregivers or family members act as gatekeepers of care
when it comes to managing medication [45]. In view of
this any discussion about stopping the warfarin therapy
should involve EF’s son. Such discussions should focus
on the risks versus benefits of warfarin therapy. It is also
important to explain that stopping the warfarin therapy
is not a sign that EF is being given up on: it should be
considered as a positive intervention, and emphasised
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that EF will be carefully monitored and put back on war-
farin if needed. If EF or her sons are not yet accepting of
her terminal illness and reduced life expectancy (previ-
ous studies refer to this acceptance as a “transition”
[45]), a possible compromise may be to stop the aspirin
therapy in the first instance. Given that EF is not adher-
ent to her aspirin therapy, and this medication does not
appear to be as important to EF or her family, this could
be a reasonable compromise. It is it is likely that depre-
scribing decisions that do not consider these factors and
don’t involve EFs sons would be unsuccessful, and cru-
cially, it may also compromise future deprescribing epi-
sodes where the context and circumstances of EF have
changed by undermining trust in the clinician.
Financial determinants
There are two financial determinants pertinent to this
case: the first is that EF purchases the calcium supple-
ments from a health food shop. The fact that she is pur-
chasing it herself should be acknowledged and
discussed, it may give her a sense of control over her
condition; and as we describe above may also provide
positive reinforcement with EF’s belief that the calcium
is ‘natural’ and ‘safe’. A possible strategy to stop the cal-
cium could explain that there is no difference between
prescribed versus over the counter calcium supplements.
The second point relating to the financial determinants
is that EF has paid for medical insurance all of her life,
and feels as though she wants something back from her
insurance – possibly by continuing to be prescribed
some of her medications. This belief should also be ac-
knowledged and discussed prior to the initiation of any
deprescribing episode. It is important to highlight to EF
that deprescribing is a positive intervention, which seeks
to improve her care. Ultimately, the decision (or not) to
undertake an episode of deprescribing should be patient
driven, and should never be about simply reducing costs
for the healthcare service.
Physical determinants
The physical determinants in this case relate to EF’s abil-
ity to take her medication. At present, she is finding it
challenging to swallow some of her medications, and
this is unlikely to improve given her disease trajectory.
Although people involved in the process of deprescribing
tend to focus on the clinical reasons for stopping medi-
cation, it is likely that, in this case, the physical chal-
lenges of taking multiple medications is having a
significant negative impact on the patient’s quality of life.
The second physical determent relates to medication
management: EF no longer has the energy to drive and
order her repeat prescriptions. In view of this, she relies
on the pharmacy to deliver her medications, but, as she
is often at hospital attending outpatient medical
appointments, she frequently misses the delivery driver.
In addition to this, the atenolol may also be causing fa-
tigue in EF, which appears to be further compounding
her tiredness. These physical determinants should be ac-
knowledged and discussed with EF: in this case, they
could be used to help initiate and promote episodes of
deprescribing. The atenolol is a good illustration of how
all of the different deprescribing determinants should be
considered as a continuum in order to achieve a success-
ful episode of deprescribing for just one of medication:
the clinical (medication has questionable benefit), the
psychological (beliefs about hypertension), the social
(relationship with her family), the financial (feels entitled
to prescribed medication), and the physical (atenolol
may be contributing to fatigue, and overall pill burden).
Conclusion
We have developed a conceptual framework to promote
effective deprescribing in the form of a rainbow, with
each segment of the rainbow representing a different
deprescribing determinant: clinical, psychological, social,
financial and physical. We believe that using the pro-
posed framework alongside existing deprescribing proto-
cols has the potential to support healthcare professionals
in their decision-making by highlighting the importance
of individual patient context within deprescribing deci-
sions. It is an initial step in an iterative process in which
the ideas proposed will be further developed by applica-
tion, investigation and refinement.
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